Scalable glycoproteomic analysis has until recently been stymied by the abundance and complexity of the generated data. Manual analysis requires massive amounts of operators’ time to derive interpretable, actionable information yet still does not address issues of accuracy and reproducibility associated with ad hoc decision making. InterVenn utilizes deep learning to automate the entire workflow, including sample processing, instrument calibration, and peak integration, all the way to run-analysis and results generation.
InterVenn's VISTATM is the first commercially available platform that can assess (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.
Site-specific measurement of protein glycoforms provides unique insights into protein attributes that traditional immunoassays or aptamer-based approaches cannot.
We enable researchers in industry and academia to rapidly and reliably assess glycan-based post-translational modifications (PTMs) at an unprecedented scale and speed without sacrificing resolution and accuracy.
See Partner Use Cases Learn More About VISTAtmGlycoprotein-based liquid biopsy assays provide unprecedented performance in clinical settings. We develop and validate novel markers to launch multiple assays that will significantly improve the patient experience, augmenting physician decision-making through novel biological insight.
Learn More about the Product Pipelines Learn More about Our VOCAL Trial (Ovarian Cancer)
